Cameron Health’s Subcutaneous ICD Sails Through FDA Advisory Panel 1

The FDA’s Circulatory System Devices panel voted 7-1 on Thursday that the benefits of the Cameron Health subcutaneous ICD system (S-ICD) outweigh the risks in appropriately selected patients.

Unlike all previous ICDs, the S-ICD is much easier to implant because it is does not require threading a lead to connect the device to the heart. Panel member Rick Lange said the S-ICD was an example of “I-should-have-thought-of-that technology”, according to Heartwire reporter Reed Miller on twitter. That sentiment was echoed by device giant Boston Scientific in March when it agreed to acquire Cameron Health for $150 million initially, and as much as $1.2 billion in additional payments based on future performance, according to Reuters.

The advisory panel also voted 7-1 that the S-ICD was effective and 8-0 that it was safe.

Earlier this week, FDA reviewers posted the previously unavailable results of the pivotal trial for the S-ICD. The FDA review set the tone for a generally supportive panel meeting, finding that the trial met its primary safety and efficacy endpoints, though it identified several potential safety issues.

Click here to read the press release from Cameron Health…

About these ads

FDA Posts Results of Cameron Subcutaneous ICD Pivotal Trial Reply

In preparation for Thursday’s meeting of the FDA’s Circulatory System Devices advisory panel, the FDA has released the results of the pivotal trial for the Cameron Health subcutaneous ICD system (S-ICD). The results have not been previously available. Unlike previous ICDs, which require threading a transvenous lead to the heart, the S-ICD system contains no leads to connect the device to the heart.

The S-ICD pivotal trial was a prospective, non-randomized, single-arm study performed at 33 sites. The trial enrolled 330 patients, 314 of whom received the S-ICD system. Mean followup was 321 days.

The FDA found that the trial met the primary safety and effectiveness endpoints.

For safety, the system-complicaton-free rate at 180 dayswas 97.9%, which was well above the performance goal of 79%. 8 patients died during the trial, but none of the deaths were tied to the S-ICD system. Four patients had systemic infections requiring explant of the device, while 14 had incision or superficial infections that did not require an explant. The FDA noted that when compared to traditional transvenous ICDs, the S-ICD system had “higher rates of infection, increased time to delivered therapy, and reduced device service life.”

Inappropriate shocks occurred in 38 patients (11.8%); 32 of these patients were managed noninvasively with system reprogramming and drug therapy. Overall, 30.6% of shocks were deemed inappropriate. The FDA reviewer said that a literature review found that about one-third of shocks were inappropriate in a similar group of patients with standard ICDs.

The efficacy rate was 100%. Acute VF conversion was successful in 304 instances, with no failures. 16 episodes were non-evaluable. The FDA calculated that even if all the non-evaluable cases were assumed to be failures, the lower confidence interval for the efficacy rate would have been 91.7%, still well above the performance goal of 88%.